From DCAT Value Chain Insights (VCI)
Alkermes plc has appointed Mark Namchuk, PhD, as senior vice president of research, pharmaceutical and nonclinical development. Dr. Namchuk will be responsible for advancing the company’s early-stage product pipeline. He will serve on the executive management team of Alkermes and report to Elliot Ehrich, MD, senior vice president of research & development and chief medical officer.
Dr. Namchuk joins Alkermes with nearly 20 years of experience in integrated R&D and drug discovery. Most recently, Dr. Namchuk served as senior vice president and interim global head of research for Vertex Pharmaceuticals, leading a group of more than 450 researchers in the areas of infectious disease, oncology, inflammatory diseases, neurology and cystic fibrosis. He has built and led departments supporting the critical components of early pharmaceutical R&D, including medicinal chemistry, protein biophysics, in vitro and in vivo pharmacology, drug metabolism, pharmacokinetics, and clinical and preclinical biomarkers. Earlier in his career, he served as the head of the biochemistry group at Cubist Pharmaceuticals.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription